POET Technologies Surges 43% on $50M Lumilens AI Optics Deal

POET Technologies (NASDAQ: POET) shares jumped 43.15% to $20.57 Thursday and extended gains to $21.62 in early extended trading Friday after Lumilens Inc. placed a $50 million initial purchase order for POET's Electrical-Optical Interposer (EOI) platform — a deal that the two companies say could scale to more than $500 million in cumulative purchases over five years.

The news provides POET with its most significant commercial validation to date — arriving at a moment the company badly needed it.

What POET and Lumilens Are Actually Building

The technology at the centre of the deal addresses a problem that is becoming impossible for AI infrastructure operators to ignore. Modern AI computing has advanced through successive integration leaps — 2.5D electrical interposers that brought GPUs and HBM into a single package, then hybrid bonding enabling today's HBM stacks.

The optical layer — how data moves between GPU clusters at data centre scale — has not made that leap. As Lumilens CEO Ankur Singla put it: "GPU interconnects are emerging as the defining bottleneck for scaling AI."

The Electrical-Optical Interposer (EOI) is POET and Lumilens's proposed solution. The platform combines POET's alignment-free wafer-level optical engine production with Lumilens's next-generation optical chipsets in a manufacturing process designed to work like semiconductor fabrication — high-volume, high-yield, capital-efficient — rather than the labour-intensive manual assembly that has constrained conventional optical module production.

The EOI roadmap spans from 800G and 1.6T pluggable transceivers to Near-Package Optics (NPO) and Co-Packaged Optics (CPO) — the most demanding optical integration technologies required for next-generation AI data centres. "Active-alignment-free manufacturing," as both companies describe it, removes what they call "the single largest cost, yield, and throughput constraint in optical engine production" by moving optical assembly to the wafer scale.

POET CEO Suresh Venkatesan framed the strategic intent: the partnership is about applying "semiconductor-style manufacturing discipline to optical engines — delivering precision, scalability, and cost structure advantages that are essential for AI infrastructure at scale."

The Deal Structure — and Why the Warrant Matters

The commercial framework is worth examining carefully. Lumilens placed a $50 million initial purchase order — that is real, committed capital.

The $500 million potential is contingent: the full value vests over five years as Lumilens makes payments on future purchase orders. To align both parties to the long-term outcome, POET granted Lumilens a warrant to purchase up to 22.9 million POET common shares at $8.25 per share over nine years. 2.29 million shares are immediately exercisable; the remainder vest in tranches tied to cumulative Lumilens payment milestones.

The warrant structure is equity alignment — Lumilens has a financial incentive to see POET's share price appreciate, which it can only achieve if it actually exercises its warrants, which requires deploying capital toward purchase orders. That creates a commercial flywheel, but it also means the $500 million figure is aspirational until Lumilens pays for it.

The timeline is explicit: engineering samples are expected in late 2026, with production ramp aligned to hyperscaler customer deployments in 2027. Revenue recognition is subject to successful module development, qualification, and manufacturing scale-up.

The Marvell Shadow — and Why the Timing Is Pointed

The Lumilens deal arrives in the immediate aftermath of a significant setback. On April 27, POET disclosed that Marvell Semiconductor cancelled all purchase orders with Celestial AI — including initial production orders — citing POET's alleged violation of confidentiality agreements around order and shipping information.

The Marvell cancellation had sent POET shares sharply lower and raised questions about the company's customer relationship management.

The Lumilens order does not erase that setback — but it provides a counter-narrative. Venkatesan cited deals with LITEON, Lessengers, and Lumilens as evidence of expanding demand for the Optical Interposer platform. The addition of Sandeep Kumar — formerly of Silicon Labs — as Chief Operating Officer starting May 11, with a mandate to build manufacturing capacity in Malaysia for high-volume output, signals operational seriousness alongside the commercial announcement.

The Financial Reality That Context Requires

POET's Q1 2026 financials provide the necessary grounding. The company posted $503,389 in non-recurring engineering and product revenue, a $12.3 million net loss, and operating cash flow negative $8.8 million.

Those are pre-commercial startup numbers. The Lumilens deal does not change the near-term financial profile — revenue recognition begins when modules are qualified and delivered, which is 2027 at earliest.

The 43% single-session surge on a $50 million order against a backdrop of sub-$600K quarterly revenue reflects the market pricing in optionality — the possibility that POET's EOI platform becomes the wafer-level optical integration standard for hyperscale AI data centres. 

That is a large addressable market. Lumentum, Coherent, and now POET and Lumilens are all competing for a portion of it.

POET's Lumilens deal is commercially real, structurally aligned, and technically credible. It is also not revenue until engineering samples clear qualification in late 2026 and production ramps in 2027. The 43% jump is the market pricing the probability that POET executes — against a company with a history of pre-revenue development-stage numbers and a recent high-profile customer relationship failure.

The warrant structure, the Malaysia manufacturing buildout, and the new COO hire are all signals of operational commitment that matter. The only thing that will ultimately validate the $500 million potential is delivery — and that clock runs through 2027.